Conditions
Hodgkin Lymphoma
Trial Purpose
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
NATIONAL TRIAL REFERENCE NUMBER
NCT03407144
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
3 - 25
Sex
All
About the trial
All patients who enroll in the trial will receive chemotherapy at the beginning of the study. Patients will be assessed after 2 cycles of chemotherapy to see how they respond to the treatment.
Patients that have an inadequate response to chemotherapy will receive study medication (pembrolizumab) in addition to continuing chemotherapy. Radiotherapy may or may not be an option.”,”Patients that have an adequate response to chemotherapy will not receive any further study treatment. Your study doctor will determine your next treatment per standard of care and will discuss this with you in more detail.
Current trial phase
Trial Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date April 9, 2018
- Estimated primary completion date February 13, 2027
- Estimated trial completion date February 13, 2027
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about